Tier 4 — mechanistic

A review on benefits of quercetin in hyperuricemia and gouty arthritis

Thanutchaporn Nutmakul
Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society 2022 30(7):918-926

Bibliography

PubMed
PMID 35903522
PubMed Central
PMC9315272
DOI
10.1016/j.jsps.2022.04.013
Funding
Funding was not specified in the indexed record or the disclosure metadata available for this entry.
Competing interests
Reported disclosure: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Study snapshot

DesignNarrative review of hyperuricemia and gout evidence
ModelNarrative or mixed evidence review
SamplePreclinical studies and limited human reports; no new cohort
InterventionQuercetin effects on urate handling and inflammatory pathways
DurationLiterature available at publication
EndpointsInflammatory measures; Uric acid

What the study showed, in plain terms

Published in 2022, this source examined uric acid and gout. Its evidence base was Preclinical studies and limited human reports; no new cohort. It evaluated Quercetin effects on urate handling and inflammatory pathways across Literature available at publication.

Potential urate-lowering and anti-inflammatory mechanisms are described alongside preliminary human evidence.

Reduced uric acid is not the same as fewer gout attacks. The review does not establish replacement of prescribed urate-lowering therapy.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin for Uric Acid and Gout: What the Trial Shows. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • Potential urate-lowering and anti-inflammatory mechanisms are described alongside preliminary human evidence.
  • The recorded outcome domains were Inflammatory measures; Uric acid.

What this study can and cannot tell us

  • Reduced uric acid is not the same as fewer gout attacks. The review does not establish replacement of prescribed urate-lowering therapy.
  • The conclusions inherit the limitations of the underlying studies. A narrative interpretation or guideline recommendation is not a new randomized treatment comparison.
  • Source basis: Source check: PubMed abstract and indexed metadata; full methods were not independently confirmed for this entry. Missing method details, funding information or participant denominators are not inferred.

Citation network

Articles citing this research paper

1 article

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology